ReviewFrontiers in oncology2025
Cardiac toxicity and intervention strategies during thoracic cancer radiotherapy.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nutritional Prevention of Oxidative Stress-Induced Cardiotoxicity in Pediatric Cardio-Oncology: Molecular Mechanisms and Translational Perspectives-A Narrative Review.International journal of molecular sciences · 2026Review
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Metabolic reprogramming in radiation-induced heart disease: the emerging role of PET imaging.Frontiers in cardiovascular medicine · 2026Review
- Cardioprotection for radiation-induced heart disease in breast cancer patients.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced heart disease (RIHD) represents a major dose-limiting complication of thoracic radiotherapy, with a multifaceted pathogenesis involving endothelial dysfunction, chronic oxidative stress, and progressive fibrotic remodeling. Emerging evidence reveals distinct molecular mechanisms underlying RIHD's heterogeneous clinical manifestations, including pericarditis, accelerated coronary artery disease, cardiomyopathy, valvular degeneration, and conduction abnormalities-which often manifest after prolonged latency periods. Modern radiotherapy techniques have reduced but not eliminated cardiac toxicity, particularly in high-risk populations. Advanced imaging modalities and biomarkers now enable earlier detection, though diagnostic challenges persist. While current management remains largely extrapolated from conventional cardiovascular therapies, novel targeted interventions show preclinical promise. This review synthesizes contemporary understanding of RIHD pathophysiology, risk stratification paradigms, and evolving cardioprotective strategies, while highlighting critical knowledge gaps requiring translational investigation to optimize outcomes for cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.